Pfizer, Gilead and others seek clarifications on trial designs outlined in FDA's UC and Crohn's draft guidance
Pharmas act to make sure their voices get heard — and before the FDA it’s no different. Especially when it relates to draft guidance.
Multiple Big …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
